end stage kidney disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years; 2. Voluntarily sign informed consent; 3. Regular peritoneal dialysis treatment for more than 3 months; 4. Initial assessment ECM/TBW>0.4, daily intake of sodium chloride 0.4 after 1 month.
Exclusion criteria
Exclusion criteria: 1. Allergy or inability to tolerate medication with Shakubactrivalsartan sodium: 2. History of symptomatic hypotension/systolic blood pressure 6.0mmol/L; 4. History of angioedema; 5. Abnormal liver function such as alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)2-3 times the upper normal limit and total bilirubin over 2 times the upper normal limit; 6. Moderate to severe anemia (hemoglobin < 60g/L); 7. Patients with advanced malignant tumor, cirrhosis and severe liver insufficiency, new severe infection, active tuberculosis, history of acute myocardial infarction within 3 months before entering the study, history of major surgical trauma within 3 months, and occurrence of peritonitis within 3 months; 8. Have hepatitis B or HIV seropositive, or are receiving immunosuppressive drugs; 9. From hemodialysis and kidney transplantation to peritoneal dialysis; 10. Receive treatment with an automatic peritoneal dialysis machine; 11. Pregnant and lactating patients or those of childbearing age who cannot guarantee effective contraception; 12. Patients suffering from mental disorders and taking psychotropic drugs; 13. The doctor assessed that the patient was not easy to follow up or had poor compliance and was not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bioimpedance body composition analysis; | — |
Countries
China
Contacts
Shanghai Oriental Hospital (Affiliated Oriental Hospital of Tongji University)